Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Shi

Showing results (31-40 of 36) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 36 results.
European Journal of Cancer (Oxford, England : 1990)|January 18, 2024
Surufatinib plus toripalimab in patients with advanced neuroendocrine tumours and neuroendocrine carcinomas: An open-label, single-arm, multi-cohort phase II trialPanpan Zhang, Si Shi, Jianming Xu, et al.
Med (New York, N.Y.)|February 1, 2025
HMPL-306 in relapsed or refractory IDH1- and/or IDH2-mutated acute myeloid leukemia: A phase 1 studyLijuan Hu, Xudong Wei, Weili Zhao, et al.
Nature Communications|December 21, 2025
Fruquintinib plus sintilimab in patients with advanced endometrial cancer with mismatch-repair proficient status: a multicenter, single-arm, phase Ib/II trialXiaohua Wu, Jing Wang, Danbo Wang, et al.
Nature Medicine|June 1, 2024
Fruquintinib plus paclitaxel versus placebo plus paclitaxel for gastric or gastroesophageal junction adenocarcinoma: the randomized phase 3 FRUTIGA trialFeng Wang, Lin Shen, Weijian Guo, et al.
Nature|October 19, 2007
Genome-wide detection and characterization of positive selection in human populationsPardis C Sabeti, Patrick Varilly, Ben Fry, et al.
Nature|October 19, 2007
A second generation human haplotype map of over 3.1 million SNPs, Kelly A Frazer, Dennis G Ballinger, et al.
Pageof 4

Showing results (31-40 of 36) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 36 results.
European Journal of Cancer (Oxford, England : 1990)|January 18, 2024
Surufatinib plus toripalimab in patients with advanced neuroendocrine tumours and neuroendocrine carcinomas: An open-label, single-arm, multi-cohort phase II trialPanpan Zhang, Si Shi, Jianming Xu, et al.
Med (New York, N.Y.)|February 1, 2025
HMPL-306 in relapsed or refractory IDH1- and/or IDH2-mutated acute myeloid leukemia: A phase 1 studyLijuan Hu, Xudong Wei, Weili Zhao, et al.
Nature Communications|December 21, 2025
Fruquintinib plus sintilimab in patients with advanced endometrial cancer with mismatch-repair proficient status: a multicenter, single-arm, phase Ib/II trialXiaohua Wu, Jing Wang, Danbo Wang, et al.
Nature Medicine|June 1, 2024
Fruquintinib plus paclitaxel versus placebo plus paclitaxel for gastric or gastroesophageal junction adenocarcinoma: the randomized phase 3 FRUTIGA trialFeng Wang, Lin Shen, Weijian Guo, et al.
Nature|October 19, 2007
Genome-wide detection and characterization of positive selection in human populationsPardis C Sabeti, Patrick Varilly, Ben Fry, et al.
Nature|October 19, 2007
A second generation human haplotype map of over 3.1 million SNPs, Kelly A Frazer, Dennis G Ballinger, et al.
Pageof 4